Sage Journals: Discover world-class research

Abstract

Spanish

French

OBJECTIVE:

To report the effect of bupropion in a patient with interferon (IFN)-induced depression and review the use of antidepressants for treatment of depressive symptoms associated with IFN therapy.

CASE SUMMARY:

A 43-year-old white woman with chronic hepatitis C and severe IFN-induced depression was treated with sustained-release bupropion initiated at 150 mg/day for 7 days and 100 mg twice daily thereafter. The dosage was increased again, to 350 mg/day when depressive symptoms recurred. While receiving that dose and continuing IFN treatment, she reported significant improvement in her depressive symptoms without experiencing any adverse effects.

DISCUSSION:

There is limited evidence suggesting that IFNs decrease central serotonergic transmission. There are several published reports on the use of selective serotonin-reuptake inhibitors for the treatment of IFN-induced depression. However, controlled studies are needed to assess the efficacy of serotonergic and noradrenergic antidepressants in IFN-treated patients with depressive symptoms.

CONCLUSIONS:

Sustained-release bupropion might be of potential benefit in patients with interferon-induced depression.

Keywords

bupropion sustained-release depression hepatitis C interferon alfa

Get full access to this article

View all access options for this article.

References

Zdilar

Franco-Bronson

Buchler

Locala

Younossi

ZM.

Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207–11.

Levenson

Fallon

HJ.

Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 1993;88:760–1.

Goldman

SL.

Successful treatment of interferon-alfa—induced depression treated with nortriptyline (letter). Psychosomatics 1994;35:412–3.

Gleason

Yates

WR.

Five cases of interferon-alpha—induced depression treated with antidepressant therapy. Psychosomatics 1999;40:510–2.

Schramm

Lawford

Macdonald

Cooksley

WGE.

Sertraline treatment of interferon-alfa—induced depressive disorder. Med J Aust 2000;173:359–61.

Kraus

Schafer

Faller

Csef

Scheurlen

Paroxetine for the treatment of interferon-α—induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091–9.

Farah

Interferon-induced depression treated with citalopram (letter). J Clin Psychiatry 2002;63:166–7.

Hosoda

Takimura

Shibayama

Kanamura

Ikeda

Kumada

Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis. Psychiatry Clin Neurosci 2000;54: 565–72.

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10–12, 2002. Hepatology 2002;36:S3–20.

10.

Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.

11.

Beck

Steer

Brown

GK.

BDI-II Manual. San Antonio, TX: Harcourt Brace, The Psychological Corporation, 1996.

12.

Antidepressants. In: Schatzberg

Cole

DeBattista

, eds. Manual of clinical psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing Inc., 2003:37–157.

13.

Chronic hepatitis C: current disease management. Bethesda, MD: National Digestive Diseases Information Clearinghouse, December 2003.

14.

Prior

Chue

PS.

Psychotic depression occurring after stopping interferon-α (letter). J Clin Psychopharmacol 1999;19:385–6.

15.

Di Bisceglie

Conjeevaram

Fried

Sallie

Park

Yurdaydin

Ribavirin as therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897–903.

16.

Davis

Esteban-Mur

Rustgi

Hoefs

Gordon

Trepo

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl J Med 1998;339:1493–9.

17.

Quitkin

McGrath

Stewart

Ocepek-Welikson

Taylor

Nunes

Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53: 785–92.

18.

Somatic treatments. In: Andreasen

Black

, eds. Introductory textbook of psychiatry. 3rd ed. Washington, DC: American Psychiatric Publishing Inc., 2001:709–59.

19.

Van Thiel

Fiedlander

De Maria

Molloy

Kania

Colantoni

Treatment of chronic hepatitis C in individuals with pre-existing or confounding neuropsychiatric disease. Hepato Gastroenterol 1998;45:328–30.

20.

Loftis

Hauser

Comanagement of depression and HCV treatment. Psychiatric Ann 2003;33:385–91.

21.

Morikawa

Sakai

Obara

Saito

Effects of interferon-α, interferon-γ and cAMP on the transcriptional regulation of serotonin transporter. Eur J Pharmacol 1998;349:317–24.

22.

Kamata

Higuchi

Yoshimoto

Yoshida

Shimizu

Effect of a single intraventricular injection of α-interferon on monoamine concentrations in the rat brain. Eur J Neuropsychopharmacol 2000;10:129–32.

23.

Werner-Felmayer

Werner

Fuchs

Hausen

Reibnegger

Wachter

Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta 1989;1012:140–7.

24.

Bonaccorso

Marino

Puzella

Pasquini

Biondi

Artini

Increased depressive ratings in patients with hepatitis C receiving interferon-α—based immunotherapy are related to interferon-α—induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86–90.

25.

Biological therapies. In: Sadock

Sadock

, eds. Kaplan & Sadock's synopsis of psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2003:974–1150.

Bupropion for Treatment of Interferon-Induced Depression